Product Description
Mechanisms of Action: Voltage-Gated Calcium Channel Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Generalized anxiety disorder|Pregnancy Outcomes|Depressive Disorder
Phase 2: Generalized anxiety disorder
Phase 1: Healthy Volunteers|Kidney Diseases|Generalized anxiety disorder|Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12617001267347p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Prostate Cancer |
None |
|||
NCT00820794 |
A5361034 | P1 |
Withdrawn |
Healthy Volunteers |
2009-06-01 |
2019-03-18 |
Treatments |
|
NCT00721422 |
A5361023 | P1 |
Terminated |
Kidney Diseases |
2009-02-01 |
2019-03-18 |
Treatments |
|
NCT00800280 |
A5361030 | P1 |
Terminated |
Generalized anxiety disorder|Healthy Volunteers |
2009-02-01 |
2025-08-27 |
||
NCT00809536 |
A5361031 | P1 |
Terminated |
Healthy Volunteers|Generalized anxiety disorder |
2009-02-01 |
2019-03-18 |
||
NCT00730145 |
A5361032 | P1 |
Completed |
Other |
2009-01-01 |
2019-03-18 |
Treatments |
|
NCT00537615 |
A5361010 | P1 |
Completed |
Generalized anxiety disorder|Healthy Volunteers |
None |
2019-03-21 |
Treatments |
|
NCT00921063 |
A5361007 | P2 |
Completed |
Generalized anxiety disorder |
2006-07-01 |
2019-03-18 |
Treatments |
|
2008-004443-11 |
2008-004443-11 | P3 |
Terminated |
Generalized anxiety disorder |
2012-01-03 |
2022-03-12 |
Treatments |
|
2008-000761-32 |
2008-000761-32 | P3 |
Terminated |
Generalized anxiety disorder |
2010-02-25 |
2022-03-12 |
Treatments |
|
2008-000762-23 |
ND | P3 |
Terminated |
Generalized anxiety disorder |
2010-01-09 |
2022-03-12 |
Treatments |
|
2008-000763-42 |
2008-000763-42 | P3 |
Terminated |
Generalized anxiety disorder |
2009-09-25 |
2025-06-28 |
Treatments |
|
NCT00735267 |
A5361022 | P3 |
Terminated |
Generalized anxiety disorder |
2009-04-01 |
2019-03-18 |
Treatments |
|
NCT00658762 |
A5361020 | P3 |
Terminated |
Generalized anxiety disorder |
2009-04-01 |
2019-03-18 |
Treatments |
|
NCT00658008 |
A5361019 | P3 |
Terminated |
Generalized anxiety disorder |
2009-03-01 |
2019-03-18 |
Treatments |
|
NCT00658372 |
A5361018 | P3 |
Terminated |
Generalized anxiety disorder |
2009-03-01 |
2019-03-18 |
Treatments |
|
NCT00738738 |
A5361036 | P3 |
Withdrawn |
Generalized anxiety disorder |
2009-02-01 |
2019-03-18 |
Treatments |
|
NCT00836069 |
NCT00836069 | P3 |
Terminated |
Depressive Disorder|Pregnancy Outcomes |
2009-02-01 |
2019-08-22 |
Primary Endpoints|Treatments |
|
NCT00542685 |
A5361017 | P3 |
Completed |
Generalized anxiety disorder |
2008-12-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|